During the second wave, we studied 170 COVID-19 patients at hospital admission, demonstrating that such patients had lower serum IL-6 levels and less severe inflammation [11] and endothelial damage [12] as compared to patients of the first wave. This evidence concerns the gene IL6 and COVID-19.